^
Association details:
| Biomarker: | NOTCH1 positive + FGFR2 mutation |
|---|---|
| Cancer: | Adenoid Cystic Carcinoma |
| Drug: | Lenvima (lenvatinib) (c-KIT inhibitor, FGFR inhibitor, VEGFR inhibitor, RET inhibitor, PDGFR α antagonist) + Balversa (erdafitinib) (FGFR inhibitor, FGFR1 inhibitor, FGFR4 inhibitor, FGFR2 inhibitor, FGFR3 inhibitor) |
| Drug Class: | γ-secretase inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Genomic profiling by cell-free circulating tumor DNA in patients with recurrent adenoid cystic carcinoma (ACC) and the potential activity of selective fibroblast growth factor receptor (FGFR) inhibitors
Published date:
05/19/2021
Excerpt:
One patient with primary lacrimal gland ACC metastatic to the liver and tNGS positive for NOTCH 1 had disease progression despite treatment with Lenvatinib and a NOTCH γ-secretase inhibitor. The patient’s ctDNA reported a FGFR2 mutation. The patient was started on Erdafitinib, an oral selective FGFR inhibitor, achieving a partial response at the primary site and metastatic liver lesions and remained on therapy for 7 months.
DOI:
10.1200/JCO.2021.39.15_suppl.e15018
